X4 Pharmaceuticals (XFOR) and Taiba Rare said Wednesday they have agreed to distribute and commercialize Xolremdi, or mavorixafor, an oral treatment for WHIM syndrome, which stands for warts, hypogammaglobulinemia, infections, and myelokathexis.
The agreement covers Saudi Arabia, the United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt.
WHIM syndrome is a rare combined primary immunodeficiency and chronic neutropenic disorder caused by a dysfunction in the CXCR4 receptor. This condition affects the movement of white blood cells from the bone marrow into the bloodstream.
The US Food and Drug Administration approved Xolremdi in April for treating WHIM syndrome in patients aged 12 and older. The European Medicines Agency is also reviewing the application, the companies said.
Taiba Rare, a division of Taiba Healthcare Group, will handle distribution, marketing, and sales while working closely with X4 on key strategic decisions.
Before full regulatory approvals, Taiba is also expected to provide Xolremdi through a named-patient compassionate use program, allowing physicians to prescribe it to patients who have no alternative treatment options.
Shares of X4 Pharmaceuticals rose more than 3% in recent trading.
Price: 0.51, Change: +0.02, Percent Change: +3.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.